These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37877369)

  • 21. The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.
    Dhaenens BAE; van Dijk SA; Taal W; Noordhoek DC; Coffey A; McKenna SP; Oostenbrink R
    J Patient Rep Outcomes; 2024 Mar; 8(1):33. PubMed ID: 38499890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects.
    Baldo F; Grasso AG; Cortellazzo Wiel L; Maestro A; Trojniak MP; Murru FM; Basso L; Magnolato A; Bruno I; Barbi E
    Paediatr Drugs; 2020 Aug; 22(4):417-423. PubMed ID: 32533336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline.
    Volontè M; Isoletta E; Gordon S; Foiadelli T; Bassanese F; Rossi A; Marseglia GL; Savasta S; Brazzelli V
    Dermatol Ther; 2022 Aug; 35(8):e15607. PubMed ID: 35638252
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study.
    Wang Z; Zhang X; Li C; Liu Y; Ge X; Zhao J; Yuan X; Li Q
    Clin Transl Med; 2024 Mar; 14(3):e1589. PubMed ID: 38456222
    [No Abstract]   [Full Text] [Related]  

  • 25. Plexiform neurofibromas.
    Korf BR
    Am J Med Genet; 1999 Mar; 89(1):31-7. PubMed ID: 10469434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of selumetinib on pediatric elephantiasis neuromatosa.
    Blegen K; Ortiz-Romero SE; Juarez O; Voeller J
    Pediatr Dermatol; 2022 Sep; 39(5):764-766. PubMed ID: 35739628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Exclusive nodular plexiform neurofibroma. An unusual case of neurofibromatosis type 1].
    Benchikhi H; Zeller J; Wolkenstein P; Wechsler J; Vidaud D; Revuz J
    Ann Dermatol Venereol; 1995; 122(9):601-3. PubMed ID: 8745684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
    Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
    Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral manifestations of neurofibromatosis type 1 in children with facial plexiform neurofibroma: report of three cases.
    Cunha KS; Rozza-de-Menezes RE; Andrade RM; Almeida L; Janini M; Geller M
    J Clin Pediatr Dent; 2015; 39(2):168-71. PubMed ID: 25823487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib.
    Caiffa T; Tessitore A; Magnolato A; Petz M; Bobbo M; Chicco D; D'Agata Mottolese B; Porcari A; Barbi E; Sinagra G; Bruno I
    Paediatr Drugs; 2023 Mar; 25(2):217-224. PubMed ID: 36529809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 34. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
    Ly KI; Merker VL; Cai W; Bredella MA; Muzikansky A; Thalheimer RD; Da JL; Orr CC; Herr HP; Morris ME; Chang CY; Harris GJ; Plotkin SR; Jordan JT
    Neurology; 2023 Feb; 100(7):e661-e670. PubMed ID: 36332985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy Volunteers.
    Zuo P; Arefayene M; Pan WJ; Freshwater T; Monteleone J
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):770-781. PubMed ID: 38591154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth behavior of plexiform neurofibromas after surgery.
    Nguyen R; Ibrahim C; Friedrich RE; Westphal M; Schuhmann M; Mautner VF
    Genet Med; 2013 Sep; 15(9):691-7. PubMed ID: 23598713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
    Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
    ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
    Vaassen P; Dürr NR; Rosenbaum T
    Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1.
    Toledano H; Dotan G; Friedland R; Cohen R; Yassur I; Toledano-Alhadef H; Constantini S; Rootman MS
    Childs Nerv Syst; 2021 Jun; 37(6):1909-1915. PubMed ID: 33751171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019.
    Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K
    Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.